Q2 FY26 · Ended Jun 30, 2026 · View SEC filing
One segment out-earns the whole company
MedSurg's segment profit is nearly twice consolidated operating income, because spin-off, legal and amortization costs sit above the segments.
For investorsWhich of this quarter's gains carry into the next ones?
For foundersBuilding a standalone company while still paying for the old one
Reported sales rose 2.2%, but a divestiture hides faster organic growth and pre-ERP ordering pulled some sales forward.
Gross profit rose on refunded tariffs, yet operating income fell 15.4% as a Bair Hugger legal accrual swelled SG&A.
Operating income fell, but lower debt cut interest expense sharply, so net income edged up to $92M.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Solventum from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
